迪哲医药：高瑞哲和Birelentinib最新研究数据在第67届美国临床血液学会发布

Core Insights - The company announced the latest research results of two globally innovative drugs at the 67th American Society of Hematology (ASH) conference, highlighting advancements in T-cell lymphoma and B-cell lymphoma treatments [1] Group 1: Drug Development - The high-selective JAK1 inhibitor, Golixtin (generic name: Golixtin capsules), has made significant progress in the field of T-cell lymphoma [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has shown promising clinical data in the treatment of B-cell lymphoma [1] Group 2: Clinical Trial Results - In the Phase III recommended dose (RP3D) of 50mg, the overall response rate (ORR) was 84.2% [1] - Tumor remission was observed in patients who had previously received BTK inhibitors, Bcl-2 inhibitors, or BTK degraders, including those with classic BTK resistance mutations (C481X) or other BTK mutations [1] - The anti-tumor efficacy was durable, and safety was good, with no new safety issues reported during the follow-up period [1]